Envveno Medical Corp (NVNO) Stock Price, Quote & News

Company Profile

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops e...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 261 2900

Website: www.envveno.com

Address:

70 Doppler, Irvine, United States

DARKP00L Jan. 14 at 7:28 PM

$NVNO this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

Icemanja Jan. 8 at 6:13 PM

$NVNO (CVI) is fundamentally a blood flow problem; they have provided Zero data to show blood flow improvement. The so called clinical improvement was only Ulcer healing not blood flow improvement. The concept of a stand alone valve has always been proven to be flawed and inconsistent. Berman himself said so in the CEO Investor segment time stamped 2m - 3:50m. A consistent reduction in reflux time, accompanied by consistent hemodynamic measurements, is the only way to approval. None of the data collected confirms a valve is the cure for CVI, this whole new trial is a roll of the dice that will be another failure.

1 · Reply

SPYmyQQQ Jan. 6 at 6:11 PM

🎯 Target Hit 🏁 📨 From Dec 10, 2025 💊 $NVNO 💵 Entry: $0.3418 ✅ Ext: $0.3934 💰 P/L: +15.10% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Icemanja Jan. 6 at 4:04 PM

$NVNO I'm so excited waiting for the RS confirmation news to drop, will it be 30:1, 40:1 or 50:1 ? Management had a celebration party planned for the day after the FDA readout. Just goes to show how inexperienced and oblivious they are to what it takes to get a product approved and what needed to be in place. And guess what, they are on track to do the same thing all over again at investors' expense . The new valve is flawed; they are scrambling to make changes , so they can keep getting paid.

0 · Reply

Icemanja Dec. 31 at 9:34 PM

$NVNO For 2025 This Award goes to non other than NVNO CEO Robert Berman and Team

1 · Reply

Ripper98 Dec. 30 at 1:04 PM

$PFSA $INTS $NVNO MY GOLDEN HOLDS STILL

0 · Reply

TradeSecretT Dec. 27 at 9:41 AM

$NVNO Markets appear to be rewarding companies that show durable execution rather than rapid narrative shifts. Resource allocation choices will signal strategic maturity. If milestones become dependable, sentiment could re‑rate quickly. Sentiment should follow confirmed results rather than headlines.

2 · Reply

Bangerplays Dec. 24 at 5:02 PM

$NVNO added starter here

0 · Reply

Ripper98 Dec. 19 at 5:40 AM

$PFSA $INTS $NVNO FAVORITES

0 · Reply

NovaX234 Dec. 17 at 4:17 PM

$NVNO taking some here looks prime and tha gap fill is beautiful

0 · Reply

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Nov 13, 2025, 5:00 PM EST - 2 months ago

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Oct 31, 2025, 8:05 AM EDT - 2 months ago

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 26, 2025, 8:45 AM EDT - 3 months ago

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 15, 2025, 8:45 AM EDT - 4 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

Aug 20, 2025, 7:00 AM EDT - 5 months ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 15, 2025, 9:21 AM EDT - 5 months ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 8:30 AM EDT - 5 months ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 4, 2025, 9:05 AM EDT - 5 months ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 1, 2025, 8:00 AM EDT - 5 months ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 22, 2025, 8:45 AM EDT - 6 months ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jun 6, 2025, 8:05 AM EDT - 7 months ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

May 19, 2025, 8:05 AM EDT - 8 months ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 13, 2025, 8:45 AM EDT - 8 months ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 1, 2025, 8:05 AM EDT - 9 months ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Apr 23, 2025, 8:00 AM EDT - 9 months ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 16, 2025, 8:30 AM EDT - 9 months ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Mar 31, 2025, 9:00 AM EDT - 10 months ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Feb 28, 2025, 8:00 AM EST - 11 months ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 19, 2025, 9:00 AM EST - 11 months ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:45 AM EST - 11 months ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 7, 2025, 9:00 AM EST - 1 year ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Dec 16, 2024, 8:50 AM EST - 1 year ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Nov 27, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 22, 2021, 7:09 AM EDT - 4 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 15, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 8, 2021, 7:43 PM EDT - 4 years ago

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 7, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 3, 2021, 8:58 AM EDT - 4 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:05 AM EDT - 4 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Jul 8, 2021, 9:05 AM EDT - 4 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Apr 23, 2021, 12:40 PM EDT - 5 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 5, 2021, 7:30 AM EDT - 5 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Jan 12, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Dec 30, 2020, 4:15 PM EST - 5 years ago

Hancock Jaffe Announces Executive Promotions

Dec 21, 2020, 8:30 AM EST - 5 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

DARKP00L Jan. 14 at 7:28 PM

$NVNO this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

Icemanja Jan. 8 at 6:13 PM

1 · Reply

SPYmyQQQ Jan. 6 at 6:11 PM

🎯 Target Hit 🏁 📨 From Dec 10, 2025 💊 $NVNO 💵 Entry: $0.3418 ✅ Ext: $0.3934 💰 P/L: +15.10% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Icemanja Jan. 6 at 4:04 PM

0 · Reply

Icemanja Dec. 31 at 9:34 PM

$NVNO For 2025 This Award goes to non other than NVNO CEO Robert Berman and Team

1 · Reply

Ripper98 Dec. 30 at 1:04 PM

$PFSA $INTS $NVNO MY GOLDEN HOLDS STILL

0 · Reply

TradeSecretT Dec. 27 at 9:41 AM

2 · Reply

Bangerplays Dec. 24 at 5:02 PM

$NVNO added starter here

0 · Reply

Ripper98 Dec. 19 at 5:40 AM

$PFSA $INTS $NVNO FAVORITES

0 · Reply

NovaX234 Dec. 17 at 4:17 PM

$NVNO taking some here looks prime and tha gap fill is beautiful

0 · Reply

Ripper98 Dec. 17 at 3:29 PM

$PFSA $PCSA $NVNO $INTS

1 · Reply

tuckerabbott Dec. 15 at 5:39 PM

$NVNO i wonder what Robert Berman thinks when he sees what he has done. What a disgrace.

3 · Reply

JohnTrack Dec. 12 at 9:18 PM

$NVNO Reverse split? total garbage! https://www.rapidticker.com/news/nvno-sec-filing-62ed51

1 · Reply

SPYmyQQQ Dec. 10 at 3:33 PM

🚀 New Signal ✅ 💊 $NVNO 🗓️ Dec 10, 2025 💵 Entry: $0.3418 🎯 Target (Opt.): $0.3934 (+15.10%) 👉 FREE TRIAL! spymyqqq/join/

1 · Reply

Ripper98 Dec. 9 at 1:51 AM

$PFSA $INTS $NVNO

0 · Reply

Ripper98 Dec. 8 at 6:32 PM

$PFSA $NVNO $INTS

0 · Reply

Icemanja Dec. 8 at 3:53 PM

$NVNO Someone please correct me if i'm wrong on these two points. Did they not say hemodynamic measurements were included in the original application? Now they say the valve Stainless Steel shell was too thick to accurately scan for hemodynamic measurements. Also before the FDA failure, myself and a few others asked how much it would cost to commercialize VenoValve at that time they said the cost would be low due to the multicenter trial and using the same pretrained doctors to roll it out. But now they state it would have cost 150 million. Since when did 150 million commercialize become low cost.

1 · Reply

Icemanja Dec. 4 at 4:02 PM

$NVNO See what the real experts with 20 years of CVI testing data and FDA approved CVI supporting products have to say about using a stand alone valve as a solution. https://www.cookmedical.com/newsroom/what-a-medical-device-company-learned-from-discontinuing-a-clinical-trial/

5 · Reply

Ripper98 Dec. 4 at 6:13 AM

$PFSA Paris conference catalyst next week $INTS $NVNO

1 · Reply

haupman Dec. 3 at 10:20 PM

$NVNO this was always the case. The good news for bagholders is there is a long term path to $5 even after they dilute. (pre R/S).

2 · Reply

haupman Dec. 3 at 9:44 PM

$NVNO good news is that they can get the hemodynamic measurements from the enVVe due to a different alloy used on the outer shell.

1 · Reply

Mr__Man Dec. 3 at 8:59 PM

$NVNO There's money to be made here

1 · Reply

Market Cap	6.79M
Revenue (ttm)	0.00
Net Income (ttm)	-21.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	402,067
Avg Vol	603,872
Day's Range	N/A - N/A
Shares Out	20.22M
Stochastic %K	28%
Beta	1.04
Analysts	Hold
Price Target	$12.50